Cancer Care Ontario | Cancer Care Ontario

You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.

Skip to main content Skip to search

403 Results

Document

radiation-timeline-funding-model.png

Jun 2024

Document

radiation-timeline-annual-reports-2016.png

Jun 2024

Document

radiation-timeline-information.png

Jun 2024

Document

radiation-timeline-radiation.png

Jun 2024

Document

radiation-timeline-annual-reports.png

Jun 2024

Document

radiation-timeline-resources-1.png

Jun 2024

Document

radiation-timeline-funding-model-1.png

Jun 2024

Document

ReturningtoWorkforGynecologicalCancerSurvivors.pdf

Jul 2024

Document

Returning-to-Work-for-Gynecological-Cancer_FR.pdf

Jul 2024

Guidelines and Advice

Initial Management of Small Cell Lung Cancer (Limited and Extensive Stage) and the Role of Thoracic Radiotherapy and First-Line Chemotherapy

Status: In-Review
ID: 7-13

Oct 2017

Drug

iMAtinib

Other Name(s): Gleevec®

Quick Link(s):

Drug Monograph, Patient Info Sheet

Dec 2024

Regimen

IMAT

Cancer Type:

Hematologic,

Leukemia - Acute Lymphoblastic (ALL)

Show More Show more tags

, Show Less Show fewer tags

Intent: Curative, Palliative

Funding:

ODB - General Benefit

iMAtinib - Refer to listed Health Canada indications for generic imatinib formulations. Patients must meet generic substitution policies for access to Gleevec®

Show More Show more tags

, Show Less Show fewer tags

Drugs Used:

... Show more tags

, Collapse Show fewer tags

Quick Link(s):

Regimen Monograph

Dec 2024

Pages